ARN-75039
/ Arisan Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 07, 2025
A Comparison of the Pharmacokinetic Properties of ARN-75039 Tablets With Excipients to Neat ARN-75039 in Hydroxypropyl Methylcellulose (HPMC) Capsules in Healthy Adult Participants Under Fed Conditions
(clinicaltrials.gov)
- P1 | N=16 | Recruiting | Sponsor: Arisan Therapeutics, Inc.
New P1 trial • Infectious Disease
January 24, 2025
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc. | Suspended ➔ Recruiting
Enrollment open • Infectious Disease
August 09, 2024
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=64 | Suspended | Sponsor: Arisan Therapeutics, Inc. | Trial completion date: Oct 2023 ➔ Apr 2025 | Recruiting ➔ Suspended | Trial primary completion date: Jul 2023 ➔ Jan 2025
Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease
February 21, 2023
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Arisan Therapeutics, Inc.
New P1 trial • Infectious Disease
1 to 4
Of
4
Go to page
1